CA3226492A1 - Bicyclic peptide inhibitors of interleukin-23 receptor - Google Patents

Bicyclic peptide inhibitors of interleukin-23 receptor Download PDF

Info

Publication number
CA3226492A1
CA3226492A1 CA3226492A CA3226492A CA3226492A1 CA 3226492 A1 CA3226492 A1 CA 3226492A1 CA 3226492 A CA3226492 A CA 3226492A CA 3226492 A CA3226492 A CA 3226492A CA 3226492 A1 CA3226492 A1 CA 3226492A1
Authority
CA
Canada
Prior art keywords
alkyl
phe
pen
cyano
thp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3226492A
Other languages
English (en)
French (fr)
Inventor
Chengzao Sun
Santhosh Neelamkavil
Raymond J. Patch
Sandeep Somani
Stephanie A. Barros
Jing Zhang
Charles HENDRICK
Elisabetta Bianchi
Roberto COSTANTE
Raffaele Ingenito
Danila Branca
Ashok Bhandari
Brian Frederick
Tran Trung Tran
Jie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Protagonist Therapeutics Inc
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Publication of CA3226492A1 publication Critical patent/CA3226492A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
CA3226492A 2021-07-14 2022-07-14 Bicyclic peptide inhibitors of interleukin-23 receptor Pending CA3226492A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221854P 2021-07-14 2021-07-14
US63/221,854 2021-07-14
PCT/US2022/037202 WO2023288017A2 (en) 2021-07-14 2022-07-14 Bicyclic peptide inhibitors of interleukin-23 receptor

Publications (1)

Publication Number Publication Date
CA3226492A1 true CA3226492A1 (en) 2023-01-19

Family

ID=84920518

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3226492A Pending CA3226492A1 (en) 2021-07-14 2022-07-14 Bicyclic peptide inhibitors of interleukin-23 receptor

Country Status (12)

Country Link
US (1) US20240352073A1 (https=)
EP (1) EP4370532A4 (https=)
JP (1) JP2024525723A (https=)
KR (1) KR20240034223A (https=)
CN (1) CN117980320A (https=)
AR (1) AR126457A1 (https=)
AU (1) AU2022310347A1 (https=)
CA (1) CA3226492A1 (https=)
MX (1) MX2024000761A (https=)
TW (1) TW202321275A (https=)
UY (1) UY39858A (https=)
WO (1) WO2023288017A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
WO2024155551A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Polycyclic peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025076414A1 (en) * 2023-10-06 2025-04-10 The Children's Medical Center Corporation Compositions and methods for selecting a subject for inflammatory bowel disease treatment
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206254B (zh) * 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10301371B2 (en) * 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
MX384213B (es) * 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
JP7100034B2 (ja) * 2016-12-06 2022-07-12 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
WO2019034866A1 (en) * 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
CN111712509A (zh) * 2017-12-15 2020-09-25 詹森生物科技公司 作为sting激动剂的环状二核苷酸
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021007433A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
JP2024525723A (ja) 2024-07-12
UY39858A (es) 2023-02-28
KR20240034223A (ko) 2024-03-13
EP4370532A2 (en) 2024-05-22
WO2023288017A3 (en) 2023-03-09
WO2023288017A2 (en) 2023-01-19
TW202321275A (zh) 2023-06-01
US20240352073A1 (en) 2024-10-24
MX2024000761A (es) 2024-04-18
CN117980320A (zh) 2024-05-03
AU2022310347A1 (en) 2024-02-29
EP4370532A4 (en) 2025-09-03
AR126457A1 (es) 2023-10-11

Similar Documents

Publication Publication Date Title
CA3226492A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
US12478617B2 (en) Lipidated peptide inhibitors of interleukin-23 receptor
CA3226539A1 (en) Peptide inhibitors of interleukin-23 receptor
JP7819087B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP7659015B2 (ja) 免疫調節剤としての１，２，４－オキサジアゾールおよびチアジアゾール化合物
TWI882061B (zh) 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
JP7670605B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP2025134806A (ja) インターロイキン２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
CA3134610A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
JP2022540154A (ja) インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
JP2018507885A (ja) 免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物
CN119255822A (zh) 靶向循环蛋白的选择性降解的双功能小分子
KR20260007614A (ko) 인터루킨-23 수용체의 펩타이드 억제제의 제조 및 이의 용도
KR20250028290A (ko) 선택적 il-23 수용체 길항제로서의 새로운 펩티드
CN107602450A (zh) 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用
HK40111925A (zh) 白介素-23受体的脂化肽抑制剂
CN121449688A (zh) 白介素-23受体的肽抑制剂及其用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603